DelveInsight is a prominent provider of valuable research within biotech and pharmaceutical industries. It offers analytical reports in such Health Care sectors as gene therapy, medical oncologic therapy, Active Pharmaceutical Ingredient (API) manufacturing, stem cell medication, biosimilars, orphan drugs and others. The expertise includes:
- Company’s profile and licensing data;
- New technology studies;
- Biologic benchmarking;
- Treatment modality analysis;
- Competitive landscape;
- Product assessment; etc.
This knowledge is essential for Generic and Drug Development companies, which also receive drug sales estimation and product performance forecasts.
DelveInsight reconciles customers need for information and for innovative approaches in business development. Consequently, the obtained data is turned into strategic design, partner up opportunities, profit earning capacity of the business. DelveInsight analysts assist pharma enterprises in launching new products and marketing development of existing pharmaceutics.
Publications found:
6,889
Sort by:
Transient Ischemic Attack - Epidemiology Forecast to 2032
US$ 3,950.00
This report can be delivered to the clients within 5-7 Business Days DelveInsight's 'Transient Ischemic Attack - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disea...
January 2022
60 pages
Transitional Cell Carcinoma - Epidemiology Forecast to 2032
US$ 3,950.00
This report can be delivered to the clients within 5-7 Business Days DelveInsight's 'Transitional Cell Carcinoma - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the dis...
January 2022
60 pages
Transverse Myelitis - Epidemiology Forecast to 2032
US$ 3,950.00
This report can be delivered to the clients within 5-7 Business Days DelveInsight's 'Transverse Myelitis - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, hi...
January 2022
60 pages
Treg cell-based Therapies - Epidemiology Forecast - 2032
US$ 3,950.00
This report can be delivered to the clients within 5-7 Business Days DelveInsight's 'Treg cell-based Therapies - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disea...
January 2022
60 pages
Trichomoniasis – Epidemiology Forecast to 2032 (US)
US$ 3,950.00
This report can be delivered to the clients within 5-7 Business Days DelveInsight's 'Trichomoniasis (US) - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, hi...
January 2022
60 pages
Trichotillomania (TTM) - Epidemiology Forecast to 2032
US$ 3,950.00
This report can be delivered to the clients within 5-7 Business Days DelveInsight's 'Trichotillomania (TTM) - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease,...
January 2022
60 pages
Trigeminal Neuralgia- Epidemiology Forecast to 2032
US$ 3,950.00
This report can be delivered to the clients within 5-7 Business Days DelveInsight's 'Trigeminal Neuralgia - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, h...
January 2022
60 pages
TRK Fusion Cancer - Epidemiology Forecast to 2032
US$ 3,950.00
This report can be delivered to the clients within 5-7 Business Days DelveInsight's 'TRK Fusion Cancer - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, hist...
January 2022
60 pages
Trk (TrkB) receptor antagonists - Pipeline Insight, 2022
US$ 1,500.00
This report can be delivered to the clients within 24 Hours DelveInsight’s, “Trk (TrkB) receptor antagonists - Pipeline Insight, 2022” report provides comprehensive insights about 3+ companies and 3...
January 2022
60 pages
TrkC receptor antagonists - Pipeline Insight, 2022
US$ 1,500.00
This report can be delivered to the clients within 2-3 Business Days DelveInsight’s, “TrkC receptor antagonists - Pipeline Insight, 2022” report provides comprehensive insights about 7+ companies an...
January 2022
60 pages
TRPV1 receptor antagonists - Pipeline Insight, 2022
US$ 1,500.00
This report can be delivered to the clients within 48 hours DelveInsight’s, “TRPV1 receptor antagonists - Pipeline Insight, 2022” report provides comprehensive insights about 4+ companies and 4+ pip...
January 2022
60 pages
Tuberous Sclerosis Complex - Epidemiology Forecast to 2032
US$ 3,950.00
This report can be delivered to the clients within 5-7 Business Days DelveInsight's 'Tuberous Sclerosis Complex - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the dise...
January 2022
60 pages
TYK2 kinase inhibitors - Pipeline Insight, 2022
US$ 1,500.00
This report can be delivered to the clients within 48 hours DelveInsight’s, “TYK2 Kinase Inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 15+ companies and 15+ pipel...
January 2022
60 pages
Type 1 Diabetes - Epidemiology Forecast - 2032
US$ 3,950.00
This report can be delivered to the clients within 5-7 Business Days DelveInsight's 'Type 1 Diabetes - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, histor...
January 2022
60 pages
Type 2 Diabetes - Epidemiology Forecast - 2032
US$ 3,950.00
This report can be delivered to the clients within 5-7 Business Days DelveInsight's 'Type 2 Diabetes - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, histor...
January 2022
60 pages
UK Healthcare Outlook Report, 2022
US$ 1,995.00
This report can be delivered to the clients within 24 Hours DelveInsight’s, “UK Healthcare Outlook 2022,” provides comprehensive insights about healthcare scenario, regulatory policies and reimburse...
January 2022
60 pages
Uncontrolled Bleeding - Epidemiology Forecast to 2032
US$ 3,950.00
This report can be delivered to the clients within 5-7 Business Days DelveInsight's 'Uncontrolled Bleeding - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease,...
January 2022
60 pages
Upper Limb Hypertonia - Epidemiology Forecast - 2032
US$ 3,950.00
This report can be delivered to the clients within 5-7 Business Days DelveInsight's 'Upper Limb Hypertonia - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease,...
January 2022
60 pages
